All News
Window of Opportunity in Psoriatic Arthritis
A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed within in less than 12 weeks) had the best clinical outcomes.
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that rheumatoid arthritis (RA) patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
Read Article
Naysayers & Disrupters
Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.
https://t.co/tm3V8U7pv4 https://t.co/R8U04urRXg
Dr. John Cush RheumNow ( View Tweet)
Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds:
- SLE (RR 1.73)
- Scleroderma (1.65)
- Psoriasis (1.48)
- Vasculitis (1.48)
- RA (1.4)
- UC &CD (~1.42)
- Sarcoid (1.42) https://t.co/RKyriK1zPe https://t.co/9F7N1jHKxX
Dr. John Cush RheumNow ( View Tweet)
According to CDC, drug overdose deaths increased in 2022 - up to 107,941, ~1% higher than the nearly 107,000 overdose deaths in 2021. 70% of these are males. 2023 numbers are not yet final but appear to be stable... https://t.co/esTuwpp4YP https://t.co/Ap5XanllU9
Dr. John Cush RheumNow ( View Tweet)
CV Risk Early with Rheumatic Disease Diagnosis
A Finnish populaton study shows that the temporal relationship between cardiovascular (CV) comorbidities in rheumatic diseases (RMD) is seen early after the RMD diagnosis.
https://t.co/GlcVJdx7Ls https://t.co/VKp6Tgqkof
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Psoriatic Arthritis Recommendations
EULAR has updated its treatment recommendations— The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.
https://t.co/0hofxzGX9O https://t.co/FXOgEJ0P0F
Dr. John Cush RheumNow ( View Tweet)
Case of Delayed Rheum Diagnosis
The Washington Post recently published a case titled, "Medical Mysteries: A rolled ankle set this runner down a painful path", which tells the tale of how/why rheums are often not consulted or consulted too late.
https://t.co/Iigmf5jdDu https://t.co/mYYm5CEvtX
Dr. John Cush RheumNow ( View Tweet)
Research on SGLT2 inhibitors in #gout is needed. They have been shown to reduce uric acid & gout flares, and may be uricosuric or be antiinflammatory. Also decreased incident gout (by half) among at-risk patients with type 2 diabetes (HR 0.54) https://t.co/ZEmhwqyDOv https://t.co/58YKD6pFyt
Dr. John Cush RheumNow ( View Tweet)
Marketing research suggests that the global rheumatoid arthritis drug market was valued at USD $17.87 billion in 2023 and is projected to reach around USD 25.67 billion by 2032 https://t.co/w4ErmjtFNV https://t.co/5bmcVJ7zh4
Dr. John Cush RheumNow ( View Tweet)
Marketing research estimates there were 1,389,116 prevalent cases of Ankylosing Spondylitis in 2017 https://t.co/bn4QHBNxEd https://t.co/BN1aNvgebS
Dr. John Cush RheumNow ( View Tweet)
Chronic MSK Pain and Earlier Retirement
Frequent musculoskeletal pain is linked with an increased risk of exiting work and retiring earlier, according to a new study published in the journal PLOS ONE.
https://t.co/wRKYjmtaAX https://t.co/n5HzbDNmGz
Dr. John Cush RheumNow ( View Tweet)
post hoc of the PEXIVAS study 704 participants w/ severe ANCA vasculitis: 92% achieved remission & 23% had relapses (rate 10.3/100PYs)-- Neither plasma exchange nor glucocorticoid tapering regimen impacted relapse risk. https://t.co/LKaqptWbxZ https://t.co/nOvE6BqYOl
Dr. John Cush RheumNow ( View Tweet)
Infection and Rituximab-linked Immunoglobulin Deficiency
A recent cohort analysis suggests that RTX-induced Ig deficiency was not associated with an increased risk of severe infection in IMID patients.
https://t.co/bNmYyYi2Vs https://t.co/MXKRbrrIJS
Dr. John Cush RheumNow ( View Tweet)
Series of Chronic Cutaneous Lupus responding to anifrolumab. 6 pts (4 DLE, 2 CCLE) betw 37-66 yrs old w/ Dz duration 10.5 yrs, 4 w/ SLE, all refractory to multiple therapies Rx w/ ANIF w/ Skin benefit. 1 developed herpes, 1 had worsening of nephritis https://t.co/6imLq3TDMu https://t.co/BMoIQhRtYs
Links:
Dr. John Cush RheumNow ( View Tweet)
Biden signs executive order on womens health research ($200 million to NIH interdisc. women res), focus on:
- integrate Women’s Health Across Federal Research prgs
- fund Research on Women’s Midlife Health
- double funding Office Womens Health Research
https://t.co/28u9lLdboL https://t.co/sld0BxsSB8
Links:
Dr. John Cush RheumNow ( View Tweet)
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. Sponsored by Novartis Pharmaceutical Corporation.
https://t.co/doSRuW0nLq https://t.co/w65jVHienh
Dr. John Cush RheumNow ( View Tweet)
4873 gout pts w/ High SUA renally typed: UA overproduct. (ROA 9%); underexcreter (RUE 61%); combined (23%) or normal (7%)
ROL: older, lower SUA, tophi & DM
RUE: lower BMI, No DM
Combined: younger, HighBMI/SUA/eGFR & smoking
Normal: older, Low SUA/eGFR https://t.co/sfcIoR0YTN https://t.co/ulqP6XyKMa
Dr. John Cush RheumNow ( View Tweet)
Post-COVID POTS? Neurology cohort study of 16 pts - 81%F, mean age 36. Common Sxs:
- Palpitations & Fatuge in 2/3
- in <1/3: migraines, IBS, Raynaud’s
- Variable tilt test but High autonomic Sxs
No insights on Rx... https://t.co/I7MLjHAUDb https://t.co/hWnfJ9WWPX
Dr. John Cush RheumNow ( View Tweet)
We're gearing up for Tuesday Night Rheumatology all April long. Register today!
Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis.
https://t.co/FeeOdxOiRQ https://t.co/FNoCi6goQS
Links:
Dr. John Cush RheumNow ( View Tweet)